Related Experiment Videos
[Construction, expression and immunogenicity study of a chimeric MS/hIL-12 eukaryotic expression plasmid]
1Department of Infectious Disease, Affiliated Hospital of Luzhou Medical College, Luzhou 646000, China.
Summary
The novel MS/hIL-12 chimeric gene vaccine significantly enhances immune responses, including higher cytokine production and cytotoxic T lymphocyte activity compared to the MS gene vaccine alone. This indicates hIL-12 improves the immunogenicity of Mtb8.4 genetic vaccines.
Area of Science:
- Molecular biology and immunology
- Genetic vaccine development
- Tuberculosis research
Context:
- Tuberculosis remains a significant global health challenge, necessitating novel vaccine strategies.
- Current vaccines have limitations in efficacy and duration of protection.
- Developing effective genetic vaccines is crucial for controlling infectious diseases.
Purpose:
- To construct and express a chimeric Mtb8.4 with signal peptide (MS)/human interleukin-12 (hIL-12) eukaryotic expression plasmid.
- To evaluate the immunogenicity of this MS/hIL-12 chimeric genetic vaccine in a mouse model.
Summary:
- A chimeric MS/hIL-12 gene was successfully constructed and expressed in vitro.
- In vivo vaccination in C57BL/6N mice demonstrated significantly higher levels of IFN-gamma and IL-2 cytokines compared to controls.
- The MS/hIL-12 vaccine also induced superior cytotoxic T lymphocyte (CTL) activity.
Impact:
- The findings suggest that incorporating hIL-12 into genetic vaccines can substantially boost immune responses.
- This strategy holds promise for developing more effective vaccines against tuberculosis and potentially other infectious diseases.
- Further research into chimeric genetic vaccines could lead to improved public health interventions.